Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks. (3rd July 2022)

• Record Type: Journal Article
• Authors: Rakotonirina, Adèle; Galperine, Tatiana; Allémann, Eric
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 7(2022)
• Page Start: 929
• Page End: 944
• Publication Date: 2022-07-03
• Subjects: Bacterial formulation -- Clostridioides difficile infection -- dysbiosis -- fecal microbiota transplantation -- live bacteria administration -- microbiota -- pharmaceutical technology; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2095901
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: The role of the gut microbiota in health and the pathogenesis of several diseases has been highlighted in recent years. Even though the precise mechanisms involving the microbiome in these ailments are still unclear, microbiota-modulating therapies have been developed. Fecal microbiota transplantation (FMT) has shown significant results against Clostridioides difficile infection (CDI), and its potential has been investigated for other diseases. Unfortunately, the technical aspects of the treatment make it difficult to implement. Pharmaceutical technology approaches to encapsulate microorganisms could play an important role in providing this treatment and render the treatment modalities easier to handle. Areas covered: After an overview of CDI, this narrative review aims to discuss the current formulations for FMT and specifically addresses the technical aspects of the treatment. This review also distinguishes itself by focusing on the hurdles and emphasizing the possible improvements using pharmaceutical technologies. Expert Opinion: FMT is an efficient treatment for recurrent CDI. However, its standardization is overlooked. The approach of industrial and hospital preparations of FMT are different, but both show promise in their respective methodologies. Novel FMT formulations could enable further research on dysbiotic diseases in the future.